Keywords: AstraZeneca, Neoprobe, Alzheimer's disease, Diagnositcs, Imaging agent, AZD4694

AstraZeneca sells imaging agent rights

Article | 13 December 2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has out-licensed AZD4694, its late-stage radiopharmaceutical imaging candidate, to USA-based Neoprobe Corp (NYSE Amex: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

AstraZeneca

Neoprobe

Go to company listing